APA (7th ed.) Citation

Zhang, S., Yi, X., Huang, L., Sun, L., Ma, J., & Han, C. (2023). Rational application of EGFR-TKI adjuvant therapy in patients with completely resected stage IB-IIIA EGFR-mutant NSCLC: A systematic review and meta-analysis of 11 randomized controlled trials. BMC Cancer, 23(1), 1. https://doi.org/10.1186/s12885-023-11194-6

Chicago Style (17th ed.) Citation

Zhang, Shu-Ling, Xiao-Fang Yi, Le-Tian Huang, Li Sun, Jie-Tao Ma, and Cheng-Bo Han. "Rational Application of EGFR-TKI Adjuvant Therapy in Patients with Completely Resected Stage IB-IIIA EGFR-mutant NSCLC: A Systematic Review and Meta-analysis of 11 Randomized Controlled Trials." BMC Cancer 23, no. 1 (2023): 1. https://doi.org/10.1186/s12885-023-11194-6.

MLA (9th ed.) Citation

Zhang, Shu-Ling, et al. "Rational Application of EGFR-TKI Adjuvant Therapy in Patients with Completely Resected Stage IB-IIIA EGFR-mutant NSCLC: A Systematic Review and Meta-analysis of 11 Randomized Controlled Trials." BMC Cancer, vol. 23, no. 1, 2023, p. 1, https://doi.org/10.1186/s12885-023-11194-6.